GlassScriptPhysician profile
Deandra D Mcduffie
NPI 1326311895
$2,969.61
in general payments reported to CMS, 2019-2025
29 companies · $999 in 2025
The $999 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $154 · 2022: $264 · 2023: $501 · 2024: $1,052 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,452 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,451.58 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $295.93 | 2022-2025 | Krystexxa, Repatha, Otezla |
| Novo Nordisk INC | $277.95 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $254.48 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Horizon Therapeutics Plc | $246.09 | 2021-2022 | |
| Astellas Pharma US INC | $239.22 | 2023-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $232.12 | 2023-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $218.38 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.40 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Janssen Pharmaceuticals, INC | $149.51 | 2024-2025 | Spravato |
| Exact Sciences Corporation | $147.07 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $127.44 | 2024-2025 | Rexulti |
| Shield Therapeutics INC | $96.14 | 2024-2025 | |
| Pfizer INC. | $92.13 | 2023-2024 | |
| Dexcom, INC. | $90.42 | 2022-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $52.27 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | $32.21 | 2023-2025 | NP Thyroid 60 |
| Currax Pharmaceuticals LLC | $30.67 | 2024-2025 | Contrave, Onzetra Xsail |
| Edwards Lifesciences Corporation | $29.38 | 2025 | Sapien 3 Ultra Resilia |
| Verity Pharmaceuticals INC. | $24.34 | 2024 | Tlando |
| Nevro Corp. | $24.14 | 2023 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.06 | 2023 | Synjardy, Tradjenta |
| Abbott Laboratories | $18.61 | 2024 | Freestyle Libre 3 |
| Cequr Corporation | $17.33 | 2024 | Cequr Simplicity |
| Glaxosmithkline, LLC. | $16.94 | 2025 | Arexvy, Shingrix |
| Tolmar, INC. | $15.90 | 2025 | Jatenzo |
| Inspire Medical Systems, INC. | $15.17 | 2025 | Inspire |
| Phadia US INC. | $14.53 | 2023 | Immunocap |
| Medtronic, INC. | $14.17 | 2022 | |
| Evofem Biosciences, INC. | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deandra Mcduffie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.